Literature DB >> 1312580

Electrophysiological studies in cerebrotendinous xanthomatosis.

Y Tokimura1, M Kuriyama, K Arimura, J Fujiyama, M Osame.   

Abstract

Seven patients with cerebrotendinous xanthomatosis (CTX) were studied by electrophysiological techniques. The percentages of abnormalities detected in nerve conduction studies and electroencephalograms were 28.6% (two patients) and 100%, respectively. All patients showed prolonged central conduction times in short latency somatosensory evoked potentials (SSEPs) by tibial nerve stimulation but normal SSEPs by median nerve stimulation. Brain stem auditory evoked potentials and visual evoked potentials were abnormal in three (42.9%) and four patients (57.1%), respectively. These electrophysiological parameters were correlated with the ratio of serum cholestanol to cholesterol concentration. The results of SSEPs suggest that the polyneuropathy in CTX is caused by distal axonopathy affecting longer axons before shorter axons (central-peripheral distal axonopathy).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1312580      PMCID: PMC488934          DOI: 10.1136/jnnp.55.1.52

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  17 in total

1.  Cholestanol deposition in cerebrotendinous xanthomatosis. A possible mechanism.

Authors:  G Salen
Journal:  Ann Intern Med       Date:  1971-12       Impact factor: 25.391

2.  Psychiatric disorders in patients with cerebrotendinous xanthomatosis.

Authors:  V M Berginer; N L Foster; M Sadowsky; J A Townsend; G J Siegel; G Salen
Journal:  Am J Psychiatry       Date:  1988-03       Impact factor: 18.112

3.  Treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid.

Authors:  T A Pedley; R G Emerson; C L Warner; L P Rowland; G Salen
Journal:  Ann Neurol       Date:  1985-10       Impact factor: 10.422

4.  De- and remyelination and onion bulb in cerebrotendinous xanthomatosis.

Authors:  A Ohnishi; Y Yamashita; I Goto; Y Kuroiwa; S Murakami; M Ikeda
Journal:  Acta Neuropathol       Date:  1979-01-12       Impact factor: 17.088

5.  Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid.

Authors:  V M Berginer; G Salen; S Shefer
Journal:  N Engl J Med       Date:  1984-12-27       Impact factor: 91.245

6.  Quantitative analysis of sterols in serum by high-performance liquid chromatography. Application to the biochemical diagnosis of cerebrotendinous xanthomatosis.

Authors:  T Kasama; D S Byun; Y Seyama
Journal:  J Chromatogr       Date:  1987-07-29

7.  Polyneuropathy with lipid deposits in Schwann cells and axonal degeneration in cerebrotendinous xanthomatosis.

Authors:  V Voiculescu; M Alexianu; G Popescu-Tismana; M Pastia; A Petrovici; A Dan
Journal:  J Neurol Sci       Date:  1987-12       Impact factor: 3.181

8.  Peripheral neuropathy in cerebrotendinous xanthomatosis.

Authors:  D A Katz; L Scheinberg; D S Horoupian; G Salen
Journal:  Arch Neurol       Date:  1985-10

9.  Cerebrotendinous xanthomatosis: a defect in mitochondrial 26-hydroxylation required for normal biosynthesis of cholic acid.

Authors:  H Oftebro; I Björkhem; S Skrede; A Schreiner; J I Pederson
Journal:  J Clin Invest       Date:  1980-06       Impact factor: 14.808

10.  Neuroaxonal pathology of central and peripheral nervous systems in cerebrotendinous xanthomatosis (CTX).

Authors:  P H Pop; E Joosten; A van Spreeken; A Gabreëls-Festen; H Jaspar; H ter Laak; A Vos
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

View more
  9 in total

1.  Polyneuropathy in cerebrotendinous xanthomatosis and response to treatment with chenodeoxycholic acid.

Authors:  F Ginanneschi; A Mignarri; M Mondelli; G N Gallus; M Del Puppo; S Giorgi; A Federico; A Rossi; M T Dotti
Journal:  J Neurol       Date:  2012-08-10       Impact factor: 4.849

2.  Cerebrotendinous xanthomatosis without tendon xanthomas mimicking Marinesco-Sjoegren syndrome: a case report.

Authors:  H R Siebner; S Berndt; B Conrad
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-05       Impact factor: 10.154

3.  Disease specific therapies in leukodystrophies and leukoencephalopathies.

Authors:  Guy Helman; Keith Van Haren; Joshua L Bonkowsky; Genevieve Bernard; Amy Pizzino; Nancy Braverman; Dean Suhr; Marc C Patterson; S Ali Fatemi; Jeff Leonard; Marjo S van der Knaap; Stephen A Back; Stephen Damiani; Steven A Goldman; Asako Takanohashi; Magdalena Petryniak; David Rowitch; Albee Messing; Lawrence Wrabetz; Raphael Schiffmann; Florian Eichler; Maria L Escolar; Adeline Vanderver
Journal:  Mol Genet Metab       Date:  2015-02-07       Impact factor: 4.797

Review 4.  Emerging treatments for pediatric leukodystrophies.

Authors:  Guy Helman; Keith Van Haren; Maria L Escolar; Adeline Vanderver
Journal:  Pediatr Clin North Am       Date:  2015-04-08       Impact factor: 3.278

Review 5.  Treatment of Smith-Lemli-Opitz syndrome and other sterol disorders.

Authors:  Melissa D Svoboda; Jill M Christie; Yasemen Eroglu; Kurt A Freeman; Robert D Steiner
Journal:  Am J Med Genet C Semin Med Genet       Date:  2012-10-05       Impact factor: 3.908

Review 6.  Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX).

Authors:  Gerald Salen; Robert D Steiner
Journal:  J Inherit Metab Dis       Date:  2017-10-04       Impact factor: 4.982

7.  The neuropathology of cerebrotendinous xanthomatosis revisited: a case report and review of the literature.

Authors:  D Soffer; D Benharroch; V Berginer
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

Review 8.  Psychiatric manifestations in cerebrotendinous xanthomatosis.

Authors:  M J Fraidakis
Journal:  Transl Psychiatry       Date:  2013-09-03       Impact factor: 6.222

9.  Cerebrotendinous Xanthomatosis: Molecular Pathogenesis, Clinical Spectrum, Diagnosis, and Disease-Modifying Treatments.

Authors:  Shingo Koyama; Yoshiki Sekijima; Masatsune Ogura; Mika Hori; Kota Matsuki; Takashi Miida; Mariko Harada-Shiba
Journal:  J Atheroscler Thromb       Date:  2021-05-08       Impact factor: 4.928

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.